Intermediate-dose prophylactic anticoagulation with low molecular weight heparin is safe after bioprosthetic artificial heart implantation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F22%3A00083436" target="_blank" >RIV/00023001:_____/22:00083436 - isvavai.cz</a>

Výsledek na webu

<a href="https://reader.elsevier.com/reader/sd/pii/S1053249822019568?token=4B62134E6FABC4AE7CF7E7185B6B3A1E6BEA268D980B19E25EFCDA740DFCB424B71A2C203AA9ECBE254844D9519C1FC7&originRegion=eu-west-1&originCreation=20221206151435" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S1053249822019568?token=4B62134E6FABC4AE7CF7E7185B6B3A1E6BEA268D980B19E25EFCDA740DFCB424B71A2C203AA9ECBE254844D9519C1FC7&originRegion=eu-west-1&originCreation=20221206151435</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.healun.2022.05.017" target="_blank" >10.1016/j.healun.2022.05.017</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Intermediate-dose prophylactic anticoagulation with low molecular weight heparin is safe after bioprosthetic artificial heart implantation

Popis výsledku v původním jazyce

Antithrombotic therapy is mandatory in standard mechanical circulatory support, usually a vitamin K antagonist and/or antiplatelet agent is used. The autoregulated Aeson total artificial heart (A-TAH, Carmat SA, Vélizy-Villacoublay, France) is designed to replace the heart in patients with end-stage heart failure. For the European pivotal study, heparin and/or LMWH was proposed with a low antiXa target starting during the first post implant days. Fifteen (n = 15) male patients were implanted between September 2016 and December 2020. Intermediate dose LMWH anticoagulation was finally used in 12 patients with a median introduction time of 29.5 (range 8-152) days after A-TAH implantation. The results suggest that an intermediate-dose prophylactic anticoagulation with LMWH is feasible with no evidence of an increase in thrombotic complications or coagulation activation in patients implanted with the autoregulated A-TAH.

Název v anglickém jazyce

Intermediate-dose prophylactic anticoagulation with low molecular weight heparin is safe after bioprosthetic artificial heart implantation

Popis výsledku anglicky

Antithrombotic therapy is mandatory in standard mechanical circulatory support, usually a vitamin K antagonist and/or antiplatelet agent is used. The autoregulated Aeson total artificial heart (A-TAH, Carmat SA, Vélizy-Villacoublay, France) is designed to replace the heart in patients with end-stage heart failure. For the European pivotal study, heparin and/or LMWH was proposed with a low antiXa target starting during the first post implant days. Fifteen (n = 15) male patients were implanted between September 2016 and December 2020. Intermediate dose LMWH anticoagulation was finally used in 12 patients with a median introduction time of 29.5 (range 8-152) days after A-TAH implantation. The results suggest that an intermediate-dose prophylactic anticoagulation with LMWH is feasible with no evidence of an increase in thrombotic complications or coagulation activation in patients implanted with the autoregulated A-TAH.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of heart and lung transplantation

ISSN

1053-2498

e-ISSN

1557-3117

Svazek periodika

41

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

4

Strana od-do

1214-1217

Kód UT WoS článku

000890162000007

EID výsledku v databázi Scopus

2-s2.0-85132800172